US.GILD · Gilead Sciences

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.8578432939042613,
        "turnoverUsdM": 1015.3632547415701,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.GILD",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 123.0316,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 2,
        "rsi_score": 2.5,
        "macd_score": 1.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.3,
      "stop_loss_percent": 5.7,
      "take_profit_price": 139.8192,
      "target_multiplier": 1.9,
      "technical_strength": 1.98,
      "take_profit_percent": 7.1
    },
    "positionPoints": 1.8,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2421954722192428,
    "stopLossPercent": 5.715686587808523,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 55.9,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 50.9,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 5
  },
  "market": {
    "ma20": 131.229,
    "ma50": 129.6018,
    "close": 130.49,
    "prevClose": 129.31,
    "avgVolume20": 6785683,
    "volumeRatio": 1.15,
    "changePercent": 0.91
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 5,
    "details": {
      "ret_5d": -0.02041888593807628,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 5,
      "vcp_bonus": 0,
      "vol_ratio": 1.0526414259682388,
      "ret_points": 0,
      "vol_points": 2,
      "range_ratio": 0.9705099278465308,
      "volat_points": 0,
      "day_range_pct": 0.02780915565873585,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 55.9,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.6,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 92,
        "contribution": 4.6
      },
      {
        "raw": 10,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 50,
        "contribution": 10
      },
      {
        "raw": 5.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 36,
        "contribution": 5.4
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 70,
        "contribution": 7
      },
      {
        "raw": 17.9,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 59.67,
        "contribution": 17.9
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 50.9,
    "details": [
      "基本面分析總分: 4.6/5分",
      "資金流分析總分: 10/20分",
      "市場環境分析總分: 5.4/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7/10分",
      "技術信號分析總分: 17.9/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4.6,
      "資金流": 10,
      "市場環境": 5.4,
      "情緒分析": 4,
      "技術信號": 17.9,
      "風險管理": 7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.5,
          "epsPoints": 0.6,
          "roePoints": 0.75,
          "debtPoints": 0.4,
          "marginPoints": 0.75,
          "turnoverUsdM": 1015.3632547415701,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 2.4,
          "obvPoints": 4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.GILD",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 710.4899991500001,
                "ma50": 717.6342017599999,
                "name": "QQQ",
                "close": 682.059998,
                "points": 0.4
              },
              "spy": {
                "ma20": 746.6545068500001,
                "ma50": 745.00220184,
                "name": "SPY",
                "close": 739.02002,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.8578432939042613,
          "atrPoints": 3,
          "cciPoints": 1.6,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141012190,
                "url": "https://finnhub.io/api/news?id=51fa8d6c7ae0b7ae5efeba304c16da4ea1ae8d7c25870a47a7c47e0f7c9348a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) closed the most recent trading day at $129.31, moving 1.18% from the previous trading session.",
                "category": "company",
                "datetime": 1784930402,
                "headline": "Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know"
              },
              {
                "id": 141004172,
                "url": "https://finnhub.io/api/news?id=320990a0a77a181b5302b8633572bf2b889ef0eb3204a5649fbc5f850ba940bc",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) offers a 2.52% dividend yield backed by strong fundamentals. With a Dividend Rating of 7/10, Profitability of 9/10, and Health of 8/10, it's a high-quality sustainable income stock.",
                "category": "company",
                "datetime": 1784891430,
                "headline": "Gilead Sciences Inc (NASDAQ:GILD): A Quality Dividend Stock for Income Investors"
              },
              {
                "id": 140979262,
                "url": "https://finnhub.io/api/news?id=9203bb8e2107fe13e333d0412f970c8c33cf9b4acec8cf74ecec2b8c1c045ac4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences plans to present new HIV research data at AIDS 2026. The presentations will include long term efficacy and safety results from lenacapavir. Gilead will also share data on a novel HIV treatment regimen developed with Merck. For investors following Gilead Sciences, NasdaqGS:GILD, the announcement connects directly to how the market views the company’s HIV portfolio. The stock recently closed at $130.28, with a return of 7.1% year to date and 21.3% over the past year. Over a 5...",
                "category": "company",
                "datetime": 1784694517,
                "headline": "Gilead (GILD) Will Bring New HIV Data And A Merck Regimen To AIDS 2026"
              },
              {
                "id": 140939218,
                "url": "https://finnhub.io/api/news?id=0e03b539cb341075b72f4a43979aac043c7a90a33c66a8f9d616252aa3870926",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "In the most recent trading session, Gilead Sciences (GILD) closed at $134.28, indicating a -1.48% shift from the previous trading day.",
                "category": "company",
                "datetime": 1784325604,
                "headline": "Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know"
              },
              {
                "id": 140921076,
                "url": "https://finnhub.io/api/news?id=e90b6781843d18b10f876394d232d07f21fe86da542e09bf98c448ef73aba319",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1784206805,
                "headline": "Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140899891,
                "url": "https://finnhub.io/api/news?id=a36ba0e144bfe82ed21483a8912f1a6bcd309292ca81b80b032aae4a07673d42",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Gilead Sciences (NASDAQ:GILD) and the best and worst performers in the therapeutics industry.",
                "category": "company",
                "datetime": 1784047151,
                "headline": "Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1"
              },
              {
                "id": 140866963,
                "url": "https://finnhub.io/api/news?id=130364ae15a54651f7e62443e98dfec75100e6eb8e4e83cc5b6689cb834b073b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "In the closing of the recent trading day, Gilead Sciences (GILD) stood at $129.83, denoting a -3.72% move from the preceding trading day.",
                "category": "company",
                "datetime": 1783720803,
                "headline": "Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts"
              },
              {
                "id": 140852250,
                "url": "https://finnhub.io/api/news?id=ac5e000deec1573246b58ef3e73dbfd5384a5818591638fbfa0eb2e7cd4c5e88",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences stock has delivered a strong 5 year run, yet current valuation checks paint a more mixed picture. The overall score sits between clearly cheap and clearly expensive, while recent oncology and HIV news keeps expectations elevated. Over the past 5 years, Gilead Sciences has returned about 140.0%, which puts more pressure on today’s valuation to be backed by durable cash flows rather than just sentiment. Regulatory approvals and positive momentum for Trodelvy and Yeztugo can...",
                "category": "company",
                "datetime": 1783609837,
                "headline": "Is Gilead Sciences (GILD) Cheap With Trodelvy And Yeztugo In Focus?"
              }
            ],
            "raw_source": [
              {
                "id": 141037700,
                "url": "https://finnhub.io/api/news?id=b8b2250a312175cf3602122142529d948bd4149b0e4de1b0847e24bcb004cddb",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Morgan Stanley  analyst Matthew Harrison   maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $166 to $165.",
                "category": "company",
                "datetime": 1785155256,
                "headline": "Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $165"
              },
              {
                "id": 141032185,
                "url": "https://finnhub.io/api/news?id=1d131c897db42ea543d59bae1c01b213e7d1915e0bbb0ee5d34da31eeea3e96a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Most biotech investors treat FBT and IBB as two names for the same trade, but the structural differences buried in their index methodologies have produced shockingly different outcomes depending on where the market's momentum actually lives.",
                "category": "company",
                "datetime": 1785151515,
                "headline": "FBT and IBB Are Not the Same Biotech Bet, and 5 Years of Returns Prove It"
              },
              {
                "id": 141034790,
                "url": "https://finnhub.io/api/news?id=7b5dd02b48d0b67861dac659a19a96bb2eae669aa76876777a2978682f3d2e39",
                "image": "https://image.cnbcfm.com/api/v1/image/108340298-17851337761785133772-47411763109-1080pnbcnews.jpg?v=1785133775&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "AstraZeneca CFO, Aradhana Sarin, discusses half-year earnings, the company's drug development pipeline, and its oral GLP-1.",
                "category": "company",
                "datetime": 1785120429,
                "headline": "AstraZeneca CFO: Very confident we will hit $80 billion revenue target"
              },
              {
                "id": 141012190,
                "url": "https://finnhub.io/api/news?id=51fa8d6c7ae0b7ae5efeba304c16da4ea1ae8d7c25870a47a7c47e0f7c9348a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) closed the most recent trading day at $129.31, moving 1.18% from the previous trading session.",
                "category": "company",
                "datetime": 1784930402,
                "headline": "Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know"
              },
              {
                "id": 141004172,
                "url": "https://finnhub.io/api/news?id=320990a0a77a181b5302b8633572bf2b889ef0eb3204a5649fbc5f850ba940bc",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) offers a 2.52% dividend yield backed by strong fundamentals. With a Dividend Rating of 7/10, Profitability of 9/10, and Health of 8/10, it's a high-quality sustainable income stock.",
                "category": "company",
                "datetime": 1784891430,
                "headline": "Gilead Sciences Inc (NASDAQ:GILD): A Quality Dividend Stock for Income Investors"
              },
              {
                "id": 141004483,
                "url": "https://finnhub.io/api/news?id=d316dc643c0ed07feab39f68d8c55616f60cc49d816ac528b488cce1d844c29d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif., July 24, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab), for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received pri",
                "category": "company",
                "datetime": 1784888760,
                "headline": "CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer"
              },
              {
                "id": 141005066,
                "url": "https://finnhub.io/api/news?id=9dacf9259e58fd1221029fce5064498f33c276a99b93ce347dbff82166b669fa",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/107429764/image_107429764.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Legend Biotech Corporation stock: strong Carvykti demand lifts Q2 sales; LB2501 CAR-T shows Phase 1 promise. Click for this LEGN update.",
                "category": "company",
                "datetime": 1784886309,
                "headline": "Legend Biotech: Why I'm Ready To Go Long Again"
              },
              {
                "id": 141005749,
                "url": "https://finnhub.io/api/news?id=f6c84623ba739cad1d4d1b8704f50b464fbf5f72330ced30f12f75dfcb3925f3",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing",
                "category": "company",
                "datetime": 1784874580,
                "headline": "Gilead Receives EMA CHMP Recommendation For Authorization For Trodelvy Plus Keytruda To Treat Metastatic Triple-Negative Breast Cancer"
              },
              {
                "id": 141005737,
                "url": "https://finnhub.io/api/news?id=09b0ee23712127e790437bd7239e1db83cc0d6bbe776a957098f94fa4e6d192b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/24/Closse-up-Shot-Of-White-Pills-On-Conveyo.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.",
                "category": "company",
                "datetime": 1784874313,
                "headline": "Two Years to Build or Pay 200% — Which US Pharma Stocks Win?"
              },
              {
                "id": 140997673,
                "url": "https://finnhub.io/api/news?id=7a6fa4d18085915d1aefb6e1292cc3e2c640721019e1a6c9e4e430ea77ab42de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "GILD's HIV franchise gains momentum with strong Biktarvy and Descovy demand, Yeztugo growth and a promising pipeline targeting long-term expansion.",
                "category": "company",
                "datetime": 1784830560,
                "headline": "Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise?"
              },
              {
                "id": 140983154,
                "url": "https://finnhub.io/api/news?id=b16daf8e0becbbc7259f8a0be20ef81eb811ce33480379e061ca6c61d8f88ee4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.",
                "category": "company",
                "datetime": 1784712780,
                "headline": "Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study"
              },
              {
                "id": 140979262,
                "url": "https://finnhub.io/api/news?id=9203bb8e2107fe13e333d0412f970c8c33cf9b4acec8cf74ecec2b8c1c045ac4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences plans to present new HIV research data at AIDS 2026. The presentations will include long term efficacy and safety results from lenacapavir. Gilead will also share data on a novel HIV treatment regimen developed with Merck. For investors following Gilead Sciences, NasdaqGS:GILD, the announcement connects directly to how the market views the company’s HIV portfolio. The stock recently closed at $130.28, with a return of 7.1% year to date and 21.3% over the past year. Over a 5...",
                "category": "company",
                "datetime": 1784694517,
                "headline": "Gilead (GILD) Will Bring New HIV Data And A Merck Regimen To AIDS 2026"
              },
              {
                "id": 140976444,
                "url": "https://finnhub.io/api/news?id=08528cb1caaaf45078de4d5021e7b14c87084d9093121bcd4bf95e728b22552c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif., July 21, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s second quarter 2026 financial results and provide a business update.",
                "category": "company",
                "datetime": 1784664300,
                "headline": "Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026"
              },
              {
                "id": 140971706,
                "url": "https://finnhub.io/api/news?id=13cc992af485499b02b200533bbc14748b649883b9c0d88c8b649afb71f397c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.",
                "category": "company",
                "datetime": 1784643746,
                "headline": "3 Market-Beating Stocks with Solid Fundamentals"
              },
              {
                "id": 140971707,
                "url": "https://finnhub.io/api/news?id=6c35cb91e508b4f8ad0dc27e911b0bcb4bcd003e8f3b449bbbc4500630a776ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif., July 21, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 26th International AIDS Conference (AIDS 2026) taking place in Rio de Janeiro, Brazil, from July 26-31. As a leader in HIV innovation, Gilead will share new scientific data from its HIV research and development programs and provide updates on its strategic initiatives and key collaborations. The data to be presented, together with Gilead-led symposia and community forums, re",
                "category": "company",
                "datetime": 1784642400,
                "headline": "Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure"
              },
              {
                "id": 140971643,
                "url": "https://finnhub.io/api/news?id=35926ea2e6b8209804ca6150c6bb35392cd2a13abf2f25b416b8779787e1d1b5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif. & RAHWAY, N.J., July 21, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (AIDS 2026). The primary endpoint results at Week 48 showed that the investigational once-weekly oral single-tablet HIV treatment regimen of islatravir 2 mg/lenacapavi",
                "category": "company",
                "datetime": 1784642400,
                "headline": "Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy"
              },
              {
                "id": 140984273,
                "url": "https://finnhub.io/api/news?id=23b2809dfaa40777c00116ff9f6b0792a5a0e6e55c1fa12bc61b4c605e91a1dc",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/21/Feb-19--2020-Foster-City--Ca--Usa.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppression through 48 weeks.",
                "category": "company",
                "datetime": 1784640481,
                "headline": "Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill"
              },
              {
                "id": 140974991,
                "url": "https://finnhub.io/api/news?id=854bfc7ad85bff420aaeb28a7ae28bdcff9fbffa47d7637a5a5081fb666f4bf5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences will release its second-quarter earnings soon, and analysts anticipate a triple-digit profit dip.",
                "category": "company",
                "datetime": 1784638566,
                "headline": "Gilead Sciences' Quarterly Earnings Preview: What You Need to Know"
              },
              {
                "id": 140984274,
                "url": "https://finnhub.io/api/news?id=1e1f5e47f53409ca122f2682f8010a0a80abd6d64584fc97a69c6f6f60ee23f5",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Leerink Partners  analyst Daina Graybosch   downgrades Gilead Sciences (NASDAQ:GILD) from Outperform to Market Perform and lowers the price target from $146 to $127.",
                "category": "company",
                "datetime": 1784637754,
                "headline": "Leerink Partners Downgrades Gilead Sciences to Market Perform, Lowers Price Target to $127"
              },
              {
                "id": 140969430,
                "url": "https://finnhub.io/api/news?id=a7decbabf581acda978185fe2485a53ac39fd75873742782db0837e286b75924",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find out which stocks got slashed and which ones earned surprise upgrades.",
                "category": "company",
                "datetime": 1784634104,
                "headline": "Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More"
              },
              {
                "id": 140965762,
                "url": "https://finnhub.io/api/news?id=6eb8b785ba528c1bad779d5d5999eb122a468b8980d539a3966a38c562564001",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.19% on an annualized basis producing an average annual return of 11.43%. Currently, Gilead Sciences has a market capitalization of",
                "category": "company",
                "datetime": 1784574049,
                "headline": "Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today"
              },
              {
                "id": 140939218,
                "url": "https://finnhub.io/api/news?id=0e03b539cb341075b72f4a43979aac043c7a90a33c66a8f9d616252aa3870926",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "In the most recent trading session, Gilead Sciences (GILD) closed at $134.28, indicating a -1.48% shift from the previous trading day.",
                "category": "company",
                "datetime": 1784325604,
                "headline": "Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know"
              },
              {
                "id": 140934498,
                "url": "https://finnhub.io/api/news?id=d5e325853357032801312770e7b99a6265e4d99d76ac402f46ae2fcc455526af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive?",
                "category": "company",
                "datetime": 1784307294,
                "headline": "Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move."
              },
              {
                "id": 140922748,
                "url": "https://finnhub.io/api/news?id=c0dfa85a65bb4922972f455c823eb8dfd1026d0cf6586ebf544156f0c2ac810d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Prediction market Kalshi is allowing users to bet on the outcomes of clinical trials and U.S. Food and Drug Adminis...",
                "category": "company",
                "datetime": 1784221200,
                "headline": "Kalshi Allows Betting On Clinical Trials And FDA Drug Decisions"
              },
              {
                "id": 140932087,
                "url": "https://finnhub.io/api/news?id=af7f0df37352e62c6b28f0323218c8c2f132887dfdfa682cfca6c2a02a0443c0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Kalshi-Hosts-Free-Groceries.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as critics warn the wagers invite insider trading.",
                "category": "company",
                "datetime": 1784208592,
                "headline": "Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings"
              },
              {
                "id": 140921076,
                "url": "https://finnhub.io/api/news?id=e90b6781843d18b10f876394d232d07f21fe86da542e09bf98c448ef73aba319",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1784206805,
                "headline": "Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140919690,
                "url": "https://finnhub.io/api/news?id=872dcdb1b794074e3c3b47d33c5b3c438dabc0540094151f4bc85d87bd2f0ffe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "(Bloomberg) -- Kalshi Inc. is expanding in biotechnology by offering wagers on the outcomes of clinical trials and regulatory decisions, giving traders a more direct way to bet on key industry catalysts.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI CompanionCIA Says AI Drones Give Russian Troops Only 30 Minutes to LiveBeckham’s IM8 Gets $1 Billion From General Catalyst for GrowthOnePlus",
                "category": "company",
                "datetime": 1784203200,
                "headline": "Kalshi Will Offer Sports-Style Betting on Drug Trial Results"
              },
              {
                "id": 140908120,
                "url": "https://finnhub.io/api/news?id=b8c6e3ec8611b248e30d1d53e25eef6984f5dfa5a8b1b6aed9bb11253f63d462",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Both Pfizer and Gilead Sciences just flashed the same ominous technical warning while trading below analyst fair value, but the reasons behind each selloff tell very different stories about which one actually deserves a second look.",
                "category": "company",
                "datetime": 1784121009,
                "headline": "Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?"
              },
              {
                "id": 140899891,
                "url": "https://finnhub.io/api/news?id=a36ba0e144bfe82ed21483a8912f1a6bcd309292ca81b80b032aae4a07673d42",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Gilead Sciences (NASDAQ:GILD) and the best and worst performers in the therapeutics industry.",
                "category": "company",
                "datetime": 1784047151,
                "headline": "Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1"
              },
              {
                "id": 140888428,
                "url": "https://finnhub.io/api/news?id=ed15eb87356bea39d17c294679a13f32dbb5cc7c416f7aa1579ca7722654403b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.",
                "category": "company",
                "datetime": 1783964231,
                "headline": "Own Regeneron For Biotech Growth? Incyte Is Making Its Case."
              },
              {
                "id": 140877198,
                "url": "https://finnhub.io/api/news?id=e3025ddb2315ad436973d69f7d2db5fb33b836836dd518e233c2710081814e73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead's expansion beyond HIV therapies will surprise many investors.",
                "category": "company",
                "datetime": 1783863780,
                "headline": "Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong."
              },
              {
                "id": 140866963,
                "url": "https://finnhub.io/api/news?id=130364ae15a54651f7e62443e98dfec75100e6eb8e4e83cc5b6689cb834b073b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "In the closing of the recent trading day, Gilead Sciences (GILD) stood at $129.83, denoting a -3.72% move from the preceding trading day.",
                "category": "company",
                "datetime": 1783720803,
                "headline": "Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts"
              },
              {
                "id": 140865010,
                "url": "https://finnhub.io/api/news?id=4c3d354a7751b7e3c25635309edaa7acf06881ecc4f247a89a15c996d87b178e",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "GILD",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1783710301,
                "headline": "What's going on in today's session: S&P500 movers"
              },
              {
                "id": 140864127,
                "url": "https://finnhub.io/api/news?id=9227f326155bc65e6ac391b8296334e42172064228b4e320a60cf8fcc20478ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "You don't need to predict a recession to prepare your portfolio. These two stocks can help.",
                "category": "company",
                "datetime": 1783700400,
                "headline": "2 Recession-Resistant Dividend Stocks to Buy and Hold"
              },
              {
                "id": 140852250,
                "url": "https://finnhub.io/api/news?id=ac5e000deec1573246b58ef3e73dbfd5384a5818591638fbfa0eb2e7cd4c5e88",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences stock has delivered a strong 5 year run, yet current valuation checks paint a more mixed picture. The overall score sits between clearly cheap and clearly expensive, while recent oncology and HIV news keeps expectations elevated. Over the past 5 years, Gilead Sciences has returned about 140.0%, which puts more pressure on today’s valuation to be backed by durable cash flows rather than just sentiment. Regulatory approvals and positive momentum for Trodelvy and Yeztugo can...",
                "category": "company",
                "datetime": 1783609837,
                "headline": "Is Gilead Sciences (GILD) Cheap With Trodelvy And Yeztugo In Focus?"
              },
              {
                "id": 140848787,
                "url": "https://finnhub.io/api/news?id=eabe957d0c0b9b815d98c056ebb784e9646d30a40a06c374e49af8d7cf98963b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (NasdaqGS:GILD) received FDA approval for Trodelvy in first line treatment of advanced triple negative breast cancer. European regulators also approved Trodelvy in the same setting for eligible patients. The company entered a partnership with BBG Advanced Therapies to deploy a mobile center offering Kite CAR T cell therapies across Texas. These updates place oncology and cell therapy firmly at the center of Gilead Sciences' story, alongside its established presence in...",
                "category": "company",
                "datetime": 1783581131,
                "headline": "Gilead Sciences (GILD) Wins Trodelvy Approvals And Expands Texas CAR T Access"
              },
              {
                "id": 140848788,
                "url": "https://finnhub.io/api/news?id=dc3466b85c9d3b577283402c50ba6938b90872fa56016a641bd868b9891d35ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) has just been removed from several Russell growth oriented indexes. This is a technical shift that can affect how some funds hold the stock and how investors view its role in portfolios. See our latest analysis for Gilead Sciences. Recent news around index removals and drug approvals has come alongside a 7.82% 7 day share price return and an 11.69% year to date share price gain for Gilead Sciences. Its 1 year total shareholder return of 23.06% and 5 year total...",
                "category": "company",
                "datetime": 1783577506,
                "headline": "Gilead Sciences (GILD) After Russell Growth Index Removal And A Fully Valued Narrative"
              },
              {
                "id": 140845528,
                "url": "https://finnhub.io/api/news?id=2aade6fef19996af1a16773a2508eaa78eb71c372e113ca6361a9b9ecbd820d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable Cheap Stocks to Buy Right Now. On June 30, Morgan Stanley kept its Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) and maintained its price target of $168. The research firm’s positive view is based on a number of factors, including the company’s growth outlook […]",
                "category": "company",
                "datetime": 1783543706,
                "headline": "Morgan Stanley Keeps Buy Rating on Gilead (GILD)"
              },
              {
                "id": 140843362,
                "url": "https://finnhub.io/api/news?id=597f4902dfd05c08eeacaf56c3d2203bd898010321778f32442a1e1312d5a219",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Major US biopharmaceutical companies' performance in the second half of the year is likely to be dri",
                "category": "company",
                "datetime": 1783529860,
                "headline": "Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says"
              },
              {
                "id": 140841649,
                "url": "https://finnhub.io/api/news?id=46cf1067762772bdaff0bf3cd43eb85b6816d116b9c6119f06b2aaa77d698dba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th",
                "category": "company",
                "datetime": 1783523510,
                "headline": "Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says"
              },
              {
                "id": 140843952,
                "url": "https://finnhub.io/api/news?id=3018272f12e8143d30f18b292420d5c4acbe0d3d8e83b86b9588d1bebf4876ac",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2253448108/image_2253448108.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Legend Biotech Corporation outlook: Carvykti drives upside in multiple myeloma, plus LB2501 optionality. Click for this updated look at LEGN stock.",
                "category": "company",
                "datetime": 1783521966,
                "headline": "A New Look At Legend Biotech: Plenty Of Upside For Carvykti"
              },
              {
                "id": 140851698,
                "url": "https://finnhub.io/api/news?id=b4e512fa99b6550d6b56cced8ce87e7d88b54232eb7304750cce6e9382f5187a",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Morgan Stanley  analyst Matthew Harrison   maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $168 to $166.",
                "category": "company",
                "datetime": 1783515400,
                "headline": "Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $166"
              },
              {
                "id": 140833905,
                "url": "https://finnhub.io/api/news?id=b7c7d72359df18e87aeb7f9f1a9c6e770753c69cfb1ebcd61539db915ac0ba41",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "GILD",
                "summary": "Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1783451100,
                "headline": "Stay informed with the top movers within the S&P500 index on Tuesday."
              },
              {
                "id": 140832952,
                "url": "https://finnhub.io/api/news?id=a07c9c4cef97cce487e30f32d0b1056e59bd7c136669ff319a0aef87895b94ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking. “There is a move in biotech that we have not ... Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”",
                "category": "company",
                "datetime": 1783441817,
                "headline": "Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”"
              },
              {
                "id": 140831554,
                "url": "https://finnhub.io/api/news?id=174db13fb0f1e19cbcbf6a1fd9f68d06644903e92d588133dbe8fd7555210271",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "BBG Advanced Therapies, a subsidiary of San Antonio-based nonprofit BioBridge Global, today announced a collaboration with Kite, a Gilead Company and global leader in cell therapy, to deploy BBG Advanced Therapies’ Mobile Leukapheresis Center (MLC) across Texas—marking an important milestone in how patients can access Kite’s CAR T-cell therapies which are individualized cancer treatments made from a patient’s own cells. BBG Advanced Therapies labs and offices BBG Advanced Therapies, a subsidiary",
                "category": "company",
                "datetime": 1783432800,
                "headline": "BBG Advanced Therapies Launches Mobile Leukapheresis Center, in Collaboration with Kite to Bring CAR T-cell Therapies Closer to Patients"
              },
              {
                "id": 140830183,
                "url": "https://finnhub.io/api/news?id=b38fed36189ed238ffbbcab24b6d07a6ef3f61ad4408f21993e1ce81ed550919",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "– Seasoned executive brings extensive leadership experience spanning corporate development, business development and pipeline strategy – – Track record includes helping build and advance leading oncology franchises at Seagen, CytomX, Gilead and Merus – CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Stipple Bio, Inc., a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, today announced the appointment of Roland Gendron as Chief Business Offi",
                "category": "company",
                "datetime": 1783429200,
                "headline": "Stipple Bio Appoints Biopharma Business Development Leader Roland Gendron as Chief Business Officer"
              },
              {
                "id": 140834932,
                "url": "https://finnhub.io/api/news?id=2246d8846ed07749cb78eab302827122938dcb09b3a7979b3be63be6fdfa28a2",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and lowers the price target from $122 to $120.",
                "category": "company",
                "datetime": 1783424369,
                "headline": "RBC Capital Maintains Sector Perform on Gilead Sciences, Lowers Price Target to $120"
              },
              {
                "id": 140830563,
                "url": "https://finnhub.io/api/news?id=db2174c073837831286ca2c07c1b3b00b29ddae31ee4aaebfa28b835704e34e6",
                "image": "",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "",
                "category": "company",
                "datetime": 1783420110,
                "headline": "SBIO: Biotech Breakthrough Opportunities Screened For Cash Burn"
              },
              {
                "id": 140834933,
                "url": "https://finnhub.io/api/news?id=6b293444e4d54d1e4f0641cbcd3d59c17c57f96329d19d1b81f439968fc0fa77",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Truist Securities  analyst Gregory Renza   maintains Gilead Sciences (NASDAQ:GILD) with a Buy and lowers the price target from $157 to $156.",
                "category": "company",
                "datetime": 1783412585,
                "headline": "Truist Securities Maintains Buy on Gilead Sciences, Lowers Price Target to $156"
              },
              {
                "id": 140823613,
                "url": "https://finnhub.io/api/news?id=6b219e38084e6475784ec645d74c2fa22bed3720375dabbf7ff1d4559a279cdd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead wins FDA approval to expand Trodelvy into first-line mTNBC, boosting its market reach and strengthening its oncology growth strategy.",
                "category": "company",
                "datetime": 1783362960,
                "headline": "Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?"
              },
              {
                "id": 140822547,
                "url": "https://finnhub.io/api/news?id=1afd47739aab53e639af99f3c3555fd4cc84a896ce09a6e979e29cf1ad07ba85",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it expects BiTAC molecules to be the company’s main value drivers and to dominate its pipeline development in the upcoming years, hence receiving VERAXA’s main share of investments to have a first BiTAC-T cell engager candidate ready by early 2028. The company stated its half-year progress […] The post The Cancer Therapy Strategy VERAXA Is Betting the Company On appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1783353653,
                "headline": "The Cancer Therapy Strategy VERAXA Is Betting the Company On"
              },
              {
                "id": 140824936,
                "url": "https://finnhub.io/api/news?id=89bd33c0e677d2320cedd19adf8992de1bb1e9b573a15c20c0d361d0e1d5ffa6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/06/Feb-19--2020-Foster-City--Ca--Usa.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "HSBC upgrades Gilead Sciences (GILD) to Buy, raising its price target to $155 on strong long-acting HIV & oncology potential.",
                "category": "company",
                "datetime": 1783346723,
                "headline": "Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says"
              },
              {
                "id": 139322844,
                "url": "https://finnhub.io/api/news?id=105e9daab0c2bd7d8ef2cbabc00e1a53c7203e51239ddad22d4c210fa5708a54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Marvell upgraded, Trade Desk downgraded: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1783345670,
                "headline": "Marvell upgraded, Trade Desk downgraded: Wall Street's top analyst calls"
              },
              {
                "id": 140819320,
                "url": "https://finnhub.io/api/news?id=35f52776660d9ec36474180a714ebba89a58bab560a35354ffec23746c014381",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th of July holiday. With second-quarter earnings starting this week, and with all of the major indices trading at or near all-time highs, you ... Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More",
                "category": "company",
                "datetime": 1783338748,
                "headline": "Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More"
              },
              {
                "id": 140820610,
                "url": "https://finnhub.io/api/news?id=2ebdc7d64c9389ba65a88d68682367fbddb2d05f928e91828f126fedcc2a0fe2",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.",
                "category": "company",
                "datetime": 1783328301,
                "headline": "Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target"
              },
              {
                "id": 140820591,
                "url": "https://finnhub.io/api/news?id=5f750f67d1264ede1d518e7585b75215f8500e34a761806577243eea842751b3",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/06/Close-Up-Of-Gilead-Sciences-Logo-And-Sig.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Wall Street analysts upgraded several top stocks, including T-Mobile, US Bancorp, Gilead Sciences, Tenable Holdings, and Murphy USA. See their ratings and price targets.",
                "category": "company",
                "datetime": 1783321476,
                "headline": "This Gilead Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday"
              },
              {
                "id": 140820612,
                "url": "https://finnhub.io/api/news?id=eafaf10ccf7ca39c18ff6de9c9a793297104b4ad0e9e3b194066cd675e25fd59",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "HSBC  analyst Morten Herholdt   upgrades Gilead Sciences (NASDAQ:GILD) from Hold to Buy and raises the price target from $133 to $155.",
                "category": "company",
                "datetime": 1783317086,
                "headline": "HSBC Upgrades Gilead Sciences to Buy, Raises Price Target to $155"
              },
              {
                "id": 140813326,
                "url": "https://finnhub.io/api/news?id=a87faf6062bae732bbb61d052b384570d5f68768c6396879fee5d5a93acbf376",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences Inc. (NASDAQ:GILD) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 25, Gilead Sciences announced FDA approval for Trodelvy as a first-line treatment for metastatic triple-negative breast cancer (mTNBC). It is now approved as a single agent or in combination with Keytruda, becoming the first antibody-drug conjugate […]",
                "category": "company",
                "datetime": 1783256348,
                "headline": "Is Gilead (GILD) One of the Most Undervalued NASDAQ Stocks to Buy Right Now?"
              },
              {
                "id": 140803221,
                "url": "https://finnhub.io/api/news?id=f9b984573fef806f0ce62d3cac8b8be11559fd8da1e60f999ea7a06beb7ac99a",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.07% on an annualized basis producing an average annual return of 11.3%. Currently, Gilead Sciences has a market capitalization of",
                "category": "company",
                "datetime": 1783080954,
                "headline": "If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 140783749,
                "url": "https://finnhub.io/api/news?id=e602ea44e0147c83c9aceac989c84a586f3fb3f31f940b5b306ac13117dc1bac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.",
                "category": "company",
                "datetime": 1782925560,
                "headline": "KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug"
              },
              {
                "id": 140772314,
                "url": "https://finnhub.io/api/news?id=e10497ea38e4fbad71eb7072d597a29bb43582fc3c78ed5ce80d21a5cf7c2964",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222148/image_2194222148.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Vertex Pharmaceuticals Incorporated offers predictable CF cash flows and pipeline catalysts in pain, hematology & renal (Pove for IgAN). Click for this VRTX update.",
                "category": "company",
                "datetime": 1782810196,
                "headline": "Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech"
              },
              {
                "id": 140761182,
                "url": "https://finnhub.io/api/news?id=d2e8a348646d5e6af80531e0527622b8d97095e08753e2f288a44d8b87ad6d68",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "GILD",
                "summary": "Gilead Sciences offers a sustainable 2.65% dividend yield with strong financial health. This article explains how to find reliable income stocks using ChartMill’s dividend, health, and profitability filters.",
                "category": "company",
                "datetime": 1782736826,
                "headline": "Gilead Sciences Inc (NASDAQ:GILD): A Sustainable Dividend Leader in the Biotechnology Sector"
              },
              {
                "id": 140761605,
                "url": "https://finnhub.io/api/news?id=711bbcaa4e6c6f8f4def15798e9b51c879c48983f3b74c54917a4d6ed5a4b9bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
                "category": "company",
                "datetime": 1782735720,
                "headline": "Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?"
              },
              {
                "id": 140750602,
                "url": "https://finnhub.io/api/news?id=f27f6b207bda2bcdc279e668a6badafa286297ecc1fd4ccaff83dd1b21071abd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]",
                "category": "company",
                "datetime": 1782605263,
                "headline": "Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC"
              },
              {
                "id": 140743691,
                "url": "https://finnhub.io/api/news?id=81c088d09dc5369db4e13083323e79094fe09aada06fa0bf6bd53a75e7bf3afd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...",
                "category": "company",
                "datetime": 1782533717,
                "headline": "Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?"
              },
              {
                "id": 140743123,
                "url": "https://finnhub.io/api/news?id=360b306066ef417a66fd2a08efe95ae65504423853afe06231bee4bb2591395e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...",
                "category": "company",
                "datetime": 1782529827,
                "headline": "Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 66,
            "discarded_article_count": 48
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.9,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.2,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(14.4%→10%)；跌縮量(近10日4日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 7702640,
              "down_days": 5,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 5874660,
              "avg_vol_20": 7392030,
              "avg_vol_30": 7702640,
              "range_pct_10": 0.09962448466361534,
              "range_pct_20": 0.12583338755204337,
              "range_pct_30": 0.14422560010532612,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.7626813663886668,
              "dist_to_20d_high": 0.07197205035203755,
              "down_shrink_days": 4,
              "breakout_level_20d": 140.61,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.6907545164718389
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 1.6,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.8578432939042613,
              "turnoverUsdM": 1015.3632547415701,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.GILD",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 123.0316,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 2,
              "rsi_score": 2.5,
              "macd_score": 1.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.3,
            "stop_loss_percent": 5.7,
            "take_profit_price": 139.8192,
            "target_multiplier": 1.9,
            "technical_strength": 1.98,
            "take_profit_percent": 7.1
          },
          "positionPoints": 1.8,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2421954722192428,
          "stopLossPercent": 5.715686587808523,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.GILD",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 3.7292,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.86
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -8.05
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.019
    },
    "kdj": {
      "d": 31.93,
      "j": 8.38,
      "k": 24.08,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 53.15
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": -39448743,
      "recentSlope": 632465.7,
      "previousSlope": -1306210
    },
    "rsi": 38.28,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 139.1718,
      "position": "SAR喺價上",
      "distancePct": 6.65,
      "previousTrend": "下降"
    },
    "ma50": 129.6018,
    "macd": {
      "macd": 0.5361522179615861,
      "trend": "中性偏多",
      "signal": 0.8581276133281264,
      "histogram": -0.3219753953665403
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 131.3105,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.15,
      "score": 6,
      "avgVolume": 6785683,
      "currentVolume": 7781157
    },
    "derived": {
      "ma20": 131.229,
      "ma50": 129.6018,
      "prevClose": 129.31,
      "avgVolume10": 6139616,
      "avgVolume20": 6785683,
      "changePercent": 0.91,
      "avgVolumeForScore": 6785683
    },
    "ma_cross": {
      "ma20": 131.229,
      "ma50": 129.6018,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 131.0985,
      "prevMa50": 129.653,
      "spreadPct": 1.26,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 125.1093,
      "upper": 137.3487,
      "position": "中間"
    },
    "rsi_short": 24.08,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.15
    }
  }
}

{
  "close": 130.49,
  "volume": 7781157,
  "changePercent": 0.91
}